279 related articles for article (PubMed ID: 25267662)
1. New colistin population pharmacokinetic data in critically ill patients suggesting an alternative loading dose rationale.
Grégoire N; Mimoz O; Mégarbane B; Comets E; Chatelier D; Lasocki S; Gauzit R; Balayn D; Gobin P; Marchand S; Couet W
Antimicrob Agents Chemother; 2014 Dec; 58(12):7324-30. PubMed ID: 25267662
[TBL] [Abstract][Full Text] [Related]
2. Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients.
Boisson M; Jacobs M; Grégoire N; Gobin P; Marchand S; Couet W; Mimoz O
Antimicrob Agents Chemother; 2014 Dec; 58(12):7331-9. PubMed ID: 25267660
[TBL] [Abstract][Full Text] [Related]
3. Colistin Population Pharmacokinetics after Application of a Loading Dose of 9 MU Colistin Methanesulfonate in Critically Ill Patients.
Karaiskos I; Friberg LE; Pontikis K; Ioannidis K; Tsagkari V; Galani L; Kostakou E; Baziaka F; Paskalis C; Koutsoukou A; Giamarellou H
Antimicrob Agents Chemother; 2015 Dec; 59(12):7240-8. PubMed ID: 26369974
[TBL] [Abstract][Full Text] [Related]
4. Population Pharmacokinetics of Colistin Methanesulfonate and Colistin in Critically Ill Patients with Acute Renal Failure Requiring Intermittent Hemodialysis.
Jacobs M; Grégoire N; Mégarbane B; Gobin P; Balayn D; Marchand S; Mimoz O; Couet W
Antimicrob Agents Chemother; 2016 Jan; 60(3):1788-93. PubMed ID: 26729492
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria.
Plachouras D; Karvanen M; Friberg LE; Papadomichelakis E; Antoniadou A; Tsangaris I; Karaiskos I; Poulakou G; Kontopidou F; Armaganidis A; Cars O; Giamarellou H
Antimicrob Agents Chemother; 2009 Aug; 53(8):3430-6. PubMed ID: 19433570
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of colistin in critically ill patients with multidrug-resistant Gram-negative bacilli infection.
Karnik ND; Sridharan K; Jadhav SP; Kadam PP; Naidu RK; Namjoshi RD; Gupta V; Gore MS; Surase PV; Mehta PR; Gogtay JA; Thatte UM; Gogtay NJ
Eur J Clin Pharmacol; 2013 Jul; 69(7):1429-36. PubMed ID: 23508665
[TBL] [Abstract][Full Text] [Related]
7. Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration.
Imberti R; Cusato M; Villani P; Carnevale L; Iotti GA; Langer M; Regazzi M
Chest; 2010 Dec; 138(6):1333-9. PubMed ID: 20558557
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetic analysis of colistin in burn patients.
Lee J; Han S; Jeon S; Hong T; Song W; Woo H; Yim DS
Antimicrob Agents Chemother; 2013 May; 57(5):2141-6. PubMed ID: 23439640
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of nebulized colistin methanesulfonate in critically ill patients.
Boisson M; Grégoire N; Cormier M; Gobin P; Marchand S; Couet W; Mimoz O
J Antimicrob Chemother; 2017 Sep; 72(9):2607-2612. PubMed ID: 28575278
[TBL] [Abstract][Full Text] [Related]
10. Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill.
Mohamed AF; Karaiskos I; Plachouras D; Karvanen M; Pontikis K; Jansson B; Papadomichelakis E; Antoniadou A; Giamarellou H; Armaganidis A; Cars O; Friberg LE
Antimicrob Agents Chemother; 2012 Aug; 56(8):4241-9. PubMed ID: 22615285
[TBL] [Abstract][Full Text] [Related]
11. Steady-state pharmacokinetic and pharmacodynamic profiling of colistin in critically ill patients with multi-drug-resistant gram-negative bacterial infections, along with differences in clinical, microbiological and safety outcome.
Ram K; Sheikh S; Bhati RK; Tripathi CD; Suri JC; Meshram GG
Basic Clin Pharmacol Toxicol; 2021 Jan; 128(1):128-140. PubMed ID: 33245629
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy and pharmacokinetics of colistimethate sodium and colistin in critically ill patients in an Indian hospital with high endemic rates of multidrug-resistant Gram-negative bacterial infections: A prospective observational study.
Moni M; Sudhir AS; Dipu TS; Mohamed Z; Prabhu BP; Edathadathil F; Balachandran S; Singh SK; Prasanna P; Menon VP; Patel T; Patel P; Kaye KS; Menon VP
Int J Infect Dis; 2020 Nov; 100():497-506. PubMed ID: 32781161
[TBL] [Abstract][Full Text] [Related]
13. Dosing of colistin-back to basic PK/PD.
Bergen PJ; Li J; Nation RL
Curr Opin Pharmacol; 2011 Oct; 11(5):464-9. PubMed ID: 21835694
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of colistin methanesulfonate and formed colistin in end-stage renal disease patients receiving continuous ambulatory peritoneal dialysis.
Koomanachai P; Landersdorfer CB; Chen G; Lee HJ; Jitmuang A; Wasuwattakul S; Sritippayawan S; Li J; Nation RL; Thamlikitkul V
Antimicrob Agents Chemother; 2014; 58(1):440-6. PubMed ID: 24189256
[TBL] [Abstract][Full Text] [Related]
15. Modified Colistin Regimen for Critically Ill Patients with Acute Renal Impairment and Continuous Renal Replacement Therapy.
Menna P; Salvatorelli E; Mattei A; Cappiello D; Minotti G; Carassiti M
Chemotherapy; 2018; 63(1):35-38. PubMed ID: 29334366
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of colistin and the relation to survival in critically ill patients infected with colistin susceptible and carbapenem-resistant bacteria.
Kristoffersson AN; Rognås V; Brill MJE; Dishon-Benattar Y; Durante-Mangoni E; Daitch V; Skiada A; Lellouche J; Nutman A; Kotsaki A; Andini R; Eliakim-Raz N; Bitterman R; Antoniadou A; Karlsson MO; Theuretzbacher U; Leibovici L; Daikos GL; Mouton JW; Carmeli Y; Paul M; Friberg LE
Clin Microbiol Infect; 2020 Dec; 26(12):1644-1650. PubMed ID: 32213316
[TBL] [Abstract][Full Text] [Related]
17. Colistin methanesulfonate and colistin pharmacokinetics in critically ill patients receiving continuous venovenous hemodiafiltration.
Karvanen M; Plachouras D; Friberg LE; Paramythiotou E; Papadomichelakis E; Karaiskos I; Tsangaris I; Armaganidis A; Cars O; Giamarellou H
Antimicrob Agents Chemother; 2013 Jan; 57(1):668-71. PubMed ID: 23147733
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients.
Garonzik SM; Li J; Thamlikitkul V; Paterson DL; Shoham S; Jacob J; Silveira FP; Forrest A; Nation RL
Antimicrob Agents Chemother; 2011 Jul; 55(7):3284-94. PubMed ID: 21555763
[TBL] [Abstract][Full Text] [Related]
19. Substantial Targeting Advantage Achieved by Pulmonary Administration of Colistin Methanesulfonate in a Large-Animal Model.
Landersdorfer CB; Nguyen TH; Lieu LT; Nguyen G; Bischof RJ; Meeusen EN; Li J; Nation RL; McIntosh MP
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27821445
[TBL] [Abstract][Full Text] [Related]
20. Greater optimisation of pharmacokinetic/pharmacodynamic parameters through a loading dose of intravenous colistin in paediatric patients.
Wacharachaisurapol N; Phasomsap C; Sukkummee W; Phaisal W; Chanakul A; Wittayalertpanya S; Chariyavilaskul P; Puthanakit T
Int J Antimicrob Agents; 2020 Jun; 55(6):105940. PubMed ID: 32179149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
